Wharton Whitney, Gleason Carey E, Lorenze Katelin R, Markgraf Tamara S, Ries Michele L, Carlsson Cynthia M, Asthana Sanjay
Am J Transl Res. 2009 Jan 20;1(2):131-47.
Over a decade of converging findings from clinical, observational and basic science research indicate that estrogen administration during the menopausal transition exerts beneficial effects on cognition and decreases a woman's risk of developing Alzheimer's disease (AD) later in life. This review article stresses the research focus of AD prevention, and introduces hormone therapy (HT) as a probable catalyst that may achieve this goal. Furthermore, this article outlines 3 mechanisms proposed to mediate estrogen's beneficial effects, discusses the controversy surrounding HT administration, and presents the most promising estrogen related research in AD prevention and treatment. Although controversial, cumulative evidence suggests that the potential of estrogen initiated during perimenopause to prevent AD needs to be systematically evaluated.
超过十年来自临床、观察性和基础科学研究的一致发现表明，在绝经过渡期间给予雌激素对认知有有益影响，并降低女性日后患阿尔茨海默病（AD）的风险。这篇综述文章强调了AD预防的研究重点，并介绍了激素疗法（HT）作为可能实现这一目标的催化剂。此外，本文概述了提出的介导雌激素有益作用的三种机制，讨论了围绕HT给药的争议，并介绍了AD预防和治疗中最有前景的雌激素相关研究。尽管存在争议，但累积证据表明，围绝经期开始的雌激素预防AD的潜力需要系统评估。
